Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy

Kaufmann, Beat A.; Goetschalckx, Kaatje; Min, Son Y.; Maeder, Micha T.; Bucher, U; Nietlispach, Fabiàn; Bernheim, Alain; Pfisterer, Matthias; Rocca, Hans‐Peter Brunner‐La

doi:10.1016/j.ijcard.2015.04.282

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TIME-CHF was a neutral study, because reduction of the primary end point according to NT-proBNP-guided versus symptom-guided therapy, ie, all-cause hospitalization event, was not achieved. Interestingly, considering repeated events of the primary end point instead of time to 1st event, NT-proBNP-guided therapy resulted in a significant benefit compared with symptom-guided therapy, which is in line with the positive findings on the disease-specific end point, 25 also found in this analysis, the positive effects on left ventricular ejection fraction, 32 the excellent safety profile, 29 and the maintained long-term effects, at least in younger patients. 28 Despite these findings, TIME-CHF obviously cannot be considered to be a positive trial on the primary end point, and the present analysis is hypothesis generating only regarding the clinical consequences.…”

Section: Potential Impact Of Considering Events-time-chf As Examplesupporting

confidence: 84%

N-Terminal Pro–B-Type Natriuretic Peptide–Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF

Davarzani

Wijk

Karel

et al. 2017

Journal of Cardiac Failure

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Potential Impact Of Considering Events-time-chf As Examplesupporting

confidence: 84%

N-Terminal Pro–B-Type Natriuretic Peptide–Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF

Davarzani

Wijk

Karel

et al. 2017

Journal of Cardiac Failure

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Figurementioning

confidence: 99%

“…Nowadays however, we know that improvement of ejection fraction and reduction of left ventricular diameters with intensified treatment is relatively common, even in elderly patients with long-standing disease. 2 Since one of the pharmacological interventions studied (i.e. sacubitril/valsartan) has improved clinical outcome as compared to standard therapy, it would have been interesting to know in how many patients QRS duration decreases over time, i.e.…”

mentioning

confidence: 99%

The importance of electrocardiographic follow‐up in heart failure

Vernooy

Rocca

2020

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…37,38 Moreover, results show that natriuretic peptide-guided therapy may improve cardiac structure and function 30,39 and that this effect is similarly present in those aged 75 years or older. 40 Thus, the effects on HF itself in HFrEF may be irrespective of age and co-morbidities, but may be to some extent concealed by events related to co-morbidities. This is in line with the lack of interaction with age in the large randomised controlled treatment trials in HF 2 , as in these trials, patients with significant co-morbidities were largely excluded.…”

Section: Odds Ratiomentioning

confidence: 99%

Biomarker Guided Therapy in Chronic Heart Failure

Rocca

Bektas

2015

Cardiac Failure Review

View full text Add to dashboard Cite

Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago, 1 there is still no real proof of the superiority of this approach as compared with standard therapy.The guidelines of the European Society of Cardiology simply state that:"several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide levels) have given conflicting results. It is uncertain whether outcome is better using this approach than by simply optimising treatment according to guidelines". Apart from being markers of function of different organs, biomarkers, mainly natriuretic peptides, are considered useful only for excluding HF and as prognostic markers.2 However, several metaanalyses, 3-6 including a very recent one based on individual patientdata (IPD), 7 have found that natriuretic peptide-guided therapy may reduce both mortality and HF related hospitalisations. However, one recent systematic review was less positive and concluded that current evidence does not support the use of B-type naturiuretic peptide (BNP) and N-terminal pro (NT-pro)BNP. to guide HF therapy.8 This review addresses current evidence of natriuretic peptide-guided therapy and discusses potential reasons why this approach needs further investigation. Moreover, it will give short insight into other emerging biomarkers that are promising for therapy guidance in chronic HF. Natriuretic Peptide Guided Heart Failure TherapyLevels of natriuretic peptides, other than BNP and the N-terminal residual of its pro-hormone NT-proBNP, have little or no clinical role in HF, at least in Europe and the US. Other biomarkers have not yet been sufficiently studied in guiding chronic therapy. Therefore, this review focuses largely on these two peptides. In order to understand the concept of natriuretic peptide-guided therapy in chronic HF several aspects are important, as summarised in a recent review.9 Thus, HF is a very costly chronic disease (around 2 % of the total healthcare budget spent for HF) with increasing prevalence (at present there about 10 million HF patients in Europe).10 Prognosis remains poor despite significant advances in therapy 11,12 and to some extent, this is related to the insufficient use of available treatment in HF.13,14 Achieving optimal therapy seems to be extremely difficult and additional markers to identify those patients in most need may be helpful. Natriuretic peptides may be very useful in this as they are strong prognostic markers across the whole spectrum of HF, particularly in the chronic stage 15 and seem to change relatively little if patients are clinically stable. 16 More importantly, natriuretic peptides change over time in parallel with change in prognosis 17,18 and treatment of chronic HF influences plasma levels of natriuretic peptides. Thus, loop diuretics, angiotensin-converting enzyme (ACE)-inhibitors, angiotensin-II receptor blockers (ARB) and mineralocorticoid receptor antagonists (MRA), as well as cardiac resynchronisation therapy (CRT), ...

show abstract

Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy

Cited by 9 publications

References 27 publications

N-Terminal Pro–B-Type Natriuretic Peptide–Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF

N-Terminal Pro–B-Type Natriuretic Peptide–Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations—Results From TIME-CHF

The importance of electrocardiographic follow‐up in heart failure

Biomarker Guided Therapy in Chronic Heart Failure

Contact Info

Product

Resources

About